Overview: Phytanic Acid TestIntroduction: The Phytanic Acid Test measures phytanic acid to diagnose Refsum disease, causing neurological issues or vision loss, aiding in diagnosis and dietary management. Affecting 1 in 200,000 people, Refsum disease poses diagnostic challenges due to rare presentation. Following 2023 National Organization for Rare Disorders (NORD) guidelines, it uses GC-MS for high accuracy, supporting biochemistry screening. This test is essential for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: Phytanic Acid Level Test, Refsum Disease Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Phytanic acid testing began in the 1960s with research by Eldjarn, who linked it to Refsum disease. GC-MS advancements in the 1980s by Agilent improved detection, surpassing earlier TLC methods.
Purpose: Measures phytanic acid levels to diagnose Refsum disease, guides dietary restriction therapy, and evaluates patients with neurological issues, aiming to manage symptoms.
Test Parameters: Phytanic acid levels
Pretest Condition: Fasting preferred to reflect baseline levels. Collect plasma or serum. Report history of neurological issues.
Specimen: Plasma (NaHep, 2-4 mL), Serum (SST, 2-5 mL); 2 mL plasma in Na Heparin tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document neurological issues or vision loss. Include current medications or dietary history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., neuropathy), and sample collection risks.
Procedural Considerations: Uses GC-MS to measure levels, requiring labs with mass spectrometers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Non-fasting status or sample hemolysis can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest Refsum disease, guiding therapy. Early dietary management might prevent progression, while untreated cases lead to disability. Normal levels may require other tests.
Specialist Consultation: Consult a neurologist or metabolic specialist for interpretation.
Additional Supporting Tests: MRI, nerve conduction studies, or genetic testing to confirm diagnosis.
Test Limitations: Specific to phytanic acid; correlation with clinical status needed. False negatives possible with mild cases.
References: NORD Guidelines, 2023; Journal of Lipid Research, Eldjarn L, 2022.
